Earnings History Data for Adamas Pharmaceuticals, Inc. (ADMS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
09-08-2021	AH	4:00 PM ET (Aug 9)	ADMS	Adamas Pharmaceuticals, Inc.	217.05	-0.27	-0.27	-0.37	Adamas Pharma EPS beats by $0.02, beats on revenue [8/9/2021 4:14 PM]	4.61	-0.49 (-9.55%)	5.10	0.0 (0.00%)	2.96 - 9.15	872,990	160,000	141
Adamas Pharma EPS beats by $0.02, beats on revenue [8/9/2021 4:14 PM] New EV battery designs unlikely to dampen metals demand, miners say [Aug-06-21 01:56PM] Adamas Reports Second Quarter 2021 Financial Results [Aug-09-21 04:01PM] Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Lags Revenue Estimates [Aug-09-21 05:15PM] Adamas Pharmaceuticals Inc (ADMS) Q2 2021 Earnings Call Transcript [Aug-10-21 12:00AM]
10-05-2021	AH	4:00 PM ET (May 10)	ADMS	Adamas Pharmaceuticals, Inc.	266.55	-0.36	-0.48	-0.59	Adamas Pharma EPS beats by $0.10, misses on revenue [5/10/2021 4:13 PM]	5.44	0.49 (9.90%)	4.95	0.0 (0.00%)	2.43 - 9.15	462,628	330,000	118
Adamas Pharma EPS beats by $0.10, misses on revenue [5/10/2021 4:13 PM] Adamas Announces New Employment Inducement Grant [May-07-21 04:05PM] Adamas Pharmaceuticals, Inc. to Host Earnings Call [May-10-21 02:30PM] Adamas Reports First Quarter 2021 Financial Results [May-10-21 04:02PM] Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates [May-10-21 05:15PM]
23-02-2021	AH	4:00 PM ET (Feb 23)	ADMS	Adamas Pharmaceuticals, Inc.	167.42	-0.64	-0.53	-0.83	Adamas Pharma EPS misses by $0.14, beats on revenue [2/23/2021 4:36 PM]	4.75	-0.39 (-7.59%)	5.42	0.28 (5.54%)	1.90 - 9.15	489,967	589,236	3,898
Adamas Pharma EPS misses by $0.14, beats on revenue [2/23/2021 4:36 PM] Adamas Pharmaceuticals launches follow-on public offering [2/24/2021 4:13 PM]
05-11-2020	AH	4:00 PM ET (Nov 5)	ADMS	Adamas Pharmaceuticals, Inc.	98.70	-0.42	-0.50	-0.99	Adamas Pharma EPS beats by $0.05, misses on revenue [11/5/2020 4:19 PM]	3.44	-0.32 (-8.51%)	3.90	0.14 (3.72%)	1.90 - 7.45	178,193	198,001	750

06-08-2020	AH	4:00 PM ET (Aug 6)	ADMS	Adamas Pharmaceuticals, Inc.	72.93	-0.37	-0.61	-0.90	Adamas Pharma EPS beats by $0.24, beats on revenue [8/6/2020 4:04 PM]	3.96	1.35 (51.85%)	3.15	0.54 (20.69%)	1.90 - 7.78	3,086,227	239,384	118,516